On 3 February 2023, the Therapeutic Goods Administration (TGA) announced a major regulatory shift that will have significant impacts for the treatment of mental health conditions. Australia is now the first country to regulate psychedelic substances as medicines on national level.[1]
In our recent article, we explored the most promising psychedelic substances, their potential therapeutic uses, and how they are currently regulated in Australia and around the world. At the time, psychedelics were prohibited substances that were only available to be used in patients enrolled in clinical research. The TGA has announced that certain psychedelics – MDMA and psilocybin (the active ingredient in ‘magic mushrooms’) – will, from 1 July 2023, be regulated as controlled drugs, meaning that they can be prescribed by approved psychiatrists for use in treating patients with certain mental health conditions.
The regulatory scheme – how it works
The Poisons Standard
The Commonwealth Poisons Standard (Poisons Standard) classifies medicines and poisons into ten schedules according to the degree of control that is exercised over their availability to the public. Each Australian state and territory has adopted the Poisons Standard. The possession, sale and supply of substances listed in the different schedules of the Poisons Standard, including psychedelics, is regulated by local state and territory legislation.
MDMA and psilocybin have, up until now, been included in Schedule 9 (Prohibited Substances) of the Poisons Standard, meaning that they were prohibited from supply (other than for use in an approved clinical trial).
The TGA’s recent decision
On 3 February 2023, the TGA confirmed that the Secretary of the Department of Health and Aged Care has decided to amend the current Poisons Standard to include MDMA and psilocybin in Schedule 8 (Controlled Drugs) with effect from 1 July this year. Following this amendment, these substances will be able to be supplied on prescription by psychiatrists approved by the TGA for use in treating patients with particular mental health conditions.
What are the circumstances in which psychedelics can be prescribed?
Psychiatrists who have been approved under the Authorised Prescriber Scheme (Scheme) will now be able to prescribe:
Psilocybin for treatment resistant depression; and
MDMA for the treatment of post-traumatic stress disorder.
There are currently no approved products containing psilocybin or MDMA on the Australian Register of Therapeutic Goods (ARTG). Following the TGA’s decision, authorised psychiatrists will be able to access and supply ‘unapproved’ medicines containing these substances for their patients under the existing Scheme.
The Authorised Prescriber Scheme
Generally, therapeutic goods must be included in the ARTG before they can be supplied in Australia. Under the Scheme however, authorised medical practitioners can supply unapproved therapeutic goods directly to patients under their immediate care without patient specific approval from the TGA.
There are two pathways under the Scheme – the ‘standard pathway’ and the ‘established history of use’ pathway.
(a) The standard pathway
For a medical practitioner to become an authorised prescriber under the standard pathway, they need to be approved by a Human Research Ethics Committee (HREC) or specialist college and apply to the TGA for approval as an authorised prescriber.
Applications for HREC approval or specialist college endorsement usually need to include evidence to justify the use of the unapproved product, including its clinical justification. Generally, where therapeutic goods are indicated for highly specific medical conditions (as is the case with psilocybin and MDMA), medical practitioners will need to demonstrate specialist experience to be approved as an authorised prescriber.
(b) The established history of use pathway
Approval from a HREC or specialist college endorsement is not required to supply products included in the list of medicines with an established history of use (published by the TGA here) under the Scheme. Psilocybin and MDMA are not currently included on the list, however, they may be in future (together with certain medicinal cannabis products that are currently included in the list).
Medical practitioners who supply products under either pathway of the Scheme are required to report the number of patients they treat to the TGA every six months.
No advertising is permitted
Psychedelics, like other prescription products, must not be advertised to the public. They may only be advertised to health professionals.
What constitutes ‘advertising’ of therapeutic goods is very broad and includes any statement, pictorial representation or design that is intended, whether directly or indirectly, to promote the use or supply of the goods. This includes material posted on the internet (including websites and in social media), articles published in newspapers and magazines, photographs, broadcast material, and displays on posters and notices.
There are very serious penalties that apply to the advertising of prescription medicines.
We anticipate that the regulatory landscape in this space will continue to shift rapidly and will continue to keep you informed.
The psilocybin industry is evolving quickly—from fringe advocacy to a multibillion-dollar wellness and medical ecosystem. With legal frameworks in Oregon, Colorado, and other states soon to follow, new careers are opening in cultivation, clinical care, compliance, education, and technology. Whether you’re looking to become a frontline facilitator or want to support psychedelic access behind the scenes, this guide outlines the top careers in psychedelics and assist you in getting a role in the industry, along with salaries, qualifications, availability, and growth potential.
2. Key Roles in the Psychedelic Ecosystem
1. Psilocybin Facilitator
Example: MycoMeditations (Jamaica) is hiring trained facilitators for therapeutic psilocybin retreats in a legal and immersive setting.What They Do: Guide clients through legal, structured psilocybin journeys in licensed centers or retreats. Qualifications: Completion of a state-certified training program, background check, and licensing exam. Salary: $75–$150/hour; $60,000–$120,000/year. Outlook: High demand as state frameworks scale.
2. Integration Coach / Psychedelic Therapist
Example: Mindbloom is actively recruiting psychedelic guides to provide therapeutic support and post-session integration.What They Do: Help clients prepare for and integrate their experiences. May or may not be involved in dosing sessions. Qualifications: Background in psychology, therapy, or coaching + specialized psychedelic training. Salary: $50–$200/hour; often private-practice or contract-based. Outlook: Growing fast with the expansion of access.
3. Clinical Director / Supervisor
What They Do: Oversee service centers, protocols, and medical oversight. Required in most legal jurisdictions. Qualifications: Licensed therapist, physician, or nurse with management experience. Salary: $80,000–$150,000/year. Outlook: Essential for scale and compliance.
4. Psychedelic Retreat Manager
What They Do: Manage operations for multi-day psychedelics retreats or service centers offering immersive psychedelic care. Qualifications: Experience in wellness, hospitality, or project management. Salary: $50,000–$90,000/year. Outlook: Strong as consumer interest grows.
5. Cultivator / Mycologist
What They Do: Grow psilocybin mushrooms legally under license for service centers or manufacturers. Qualifications: Background in agriculture, mycology, or indoor cultivation. Salary: $40,000–$70,000/year. Outlook: Limited by regulation; high entry barrier but foundational.
6. Compliance & Licensing Officer
Example: Oregon Psilocybin Services recently posted a position for a Compliance Program Manager overseeing adherence to state policies.What They Do: Ensure organizations meet legal and operational requirements (similar to cannabis industry roles). Qualifications: Background in legal, policy, or regulatory affairs. Salary: $60,000–$110,000/year. Outlook: In-demand across retreat centers, clinics, and producers.
7. Psychedelic Educator / Curriculum Developer
What They Do: Design content and courses for facilitators, therapists, and the general public. Qualifications: Education or counseling background with psychedelic experience. Salary: $25–$100/hour or salaried at $40,000–$85,000/year. Outlook: Expanding rapidly with demand for trained professionals.
8. Lab Technician / Psilocybin Manufacturer
What They Do: Process mushrooms into pharmaceutical-grade materials or perform extraction/synthesis. Qualifications: Biotech, chemistry, or pharma experience. Salary: $50,000–$95,000/year. Outlook: Growing in clinical and biotech sectors.
Careers in Psychedelics
9. Tech Developer / Platform Designer
What They Do: Build apps and platforms for integration, education, remote support, and biometric tracking. Qualifications: Healthtech, software, or UI/UX background. Salary: $70,000–$150,000/year (plus equity in startups). Outlook: Booming with venture-backed growth.
10. Advocacy & Community Outreach
What They Do: Organize local education campaigns, help pass decrim bills, and promote access equity. Qualifications: Grassroots or nonprofit organizing experience. Salary: $30,000–$70,000/year. Often grant-funded. Outlook: Core to the movement’s ethical foundation.
3. Additional Career Paths in the Psychedelic Space
11. Psychedelic Integration Coach
What They Do: Help clients mentally and emotionally integrate psychedelic insights after sessions. Qualifications: Coaching background, mental health training, psychedelic-specific coursework. Salary: $50–$200/hour. Outlook: Rapid growth due to consumer demand for post-session support.
12. Clinical Research Coordinator
Example: USC is hiring coordinators for studies on mindfulness-assisted psychedelic therapy, managing logistics and research integrity.What They Do: Manage logistics, compliance, and administration of clinical trials related to psilocybin. Qualifications: Bachelor’s or Master’s in life sciences; clinical research certification. Salary: $67,000–$88,000/year. Outlook: High demand with ongoing FDA trials and research studies.
13. Psychedelic Nurse
Example: Cardinal Health lists roles for psychedelic patient education nurses involved in remote and clinical support roles.What They Do: Provide medical monitoring during clinical or therapeutic psilocybin sessions. Qualifications: RN license; optional additional training in psychedelic therapy. Salary: $44,000–$140,000/year depending on setting and role. Outlook: Increasing need as more clinics include clinical staff.
14. Psychedelic Event Organizer
What They Do: Coordinate workshops, retreats, and conferences focused on psychedelic healing and culture. Qualifications: Event planning, operations, and understanding of safe psychedelic practices. Salary: Variable; often project-based or freelance. Outlook: Strong potential as community engagement grows.
15. Psychedelic Media Producer / Educator
What They Do: Create content (video, podcasts, articles) to educate the public and reduce stigma. Qualifications: Media production skills, communication background, psychedelic literacy. Salary: $55,000–$65,000/year or freelance/project based. Outlook: Expanding alongside public interest in psychedelics.
16. Psychedelic Recruiter
What They Do: Source talent for psychedelic startups, clinics, and training programs. Qualifications: HR or recruitment experience; familiarity with licensing and regulatory requirements. Salary: Competitive; often salary plus commission. Outlook: Increasing demand with industry expansion.
17. Psychedelic Policy Advocate
What They Do: Lobby for policy reform, decriminalization, and expanded access to psychedelics. Qualifications: Legal or political science background; advocacy experience. Salary: Varies by nonprofit funding or consulting structure. Outlook: Essential for shaping the movement’s trajectory.
4. Emerging Roles to Watch
AI-Assisted Trip Support Specialists Combining biometric data and predictive tools to enhance safety.
Psychedelic HR & DEI Officers Ensuring cultural competency and workforce inclusion in psychedelic companies.
Connect on platforms like LinkedIn, Guild, and psychedelic Slack channels
Specialize and Apply
Develop a niche (e.g., equity, integration, policy, data science)
Join early-stage companies, consult, or contribute as a freelancer
Persistence, humility, and clear intentions go a long way—this is an industry built not just on opportunity, but on care, ethics, and transformation.
Careers in Psychedelics
7. Careers in Psychedelics – Final Thoughts
From scientific labs to forest retreats, the legal psilocybin industry is building the infrastructure for a future rooted in care, ethics, and innovation. Whether you’re a clinician, educator, cultivator, or coder, there is likely a role for you in this historic movement.
As access expands, new job categories will emerge—blending healthcare, spirituality, tech, agriculture, and law in unprecedented ways. Early movers in these fields won’t just shape an industry—they’ll help redefine wellness for a generation.
Unique NY-Born Licensing Model for Therapeutic Psilocybin Use Gains Momentum in State Senate Amid Flurry of Psychedelic Bills Filed Across the US
(Albany, NY) As New York’s cannabis industry continues to turn a hefty profit in the earliest days of 2025 so far, many plant medicine community members both within and just beyond the cannabis industry have been steadily laying the groundwork for the next state-level drug policy reform movement rife with seemingly-incompatible, arguably-intertwined intersectional equity enhancement opportunities and profit margin maximization priorities at play: psychedelics.
For those unfamiliar, 2024 brought about a number of presumed-to-be momentum-stalling psychedelic setbacks – first with the FDA’s stunning rejection of a first-of-its-kind MDMA-Assisted Therapy Treatment developed by the Multidisciplinary Association of Psychedelic Studies (MAPS) and their Public Benefit Corporation (PBC) spin-off Lykos Therapeutics. To compound public misperception of psychedelic policy reform efforts further, a much-discussed and deep-pocketed legal psychedelic therapy-personal possession and home cultivation decrim-focused psychedelic ballot campaign in Massachusetts failed spectacularly – leading some pundits – both pro-legalization and prohibitionists alike – to speculate that “the psychedelic renaissance” as it’s been called by some, had in fact stalled out at large.
Fortunately for the plant medicine community, those naysayers were largely wrong, as in January 2025 alone, a record-breaking 38 psychedelics-related bills were filed in 14 states across the country. Here in New York, prominent psychedelic policy reform advocates have gained serious traction within the state’s legislature, especially after a recent lobbying day at the state Capitol.
Led by the increasingly diverse coalition known as New Yorkers for Mental Health Alternatives and backed by a growing bipartisan interest in alternative mental health treatments, New York’s burgeoning intersectional community of psychedelic activists and legal experts recently gathered in Albany to rally support for two proposed bills aimed at expanding access to psychedelics for therapeutic and personal use.
Avery Stempel NYMHA
“Our 2025 New York State Capitol Lobby Day was a huge success,” said Avery Stempel, co-founder of New Yorkers for Mental Health Alternatives (NYMHA) and founder of Collar City Mushrooms. “Advocates, doctors, and lawyers from Brooklyn to Buffalo traveled to Albany to participate. We had individual meetings with 10 senators and assembly members and talked to many more in the hall while they passed by our tables. There is a lot of energy gathering around the New York bills, and we are hopeful that we will be making some serious traction this year.”
At the forefront of the legislative push is Assembly Bill A2142, introduced by Assemblywoman Amy Paulin (D) alongside four co-sponsors. The bill would create a state-supervised program allowing licensed facilitators, including health and social care professionals, to administer psilocybin-assisted therapy to eligible patients. The measure mirrors a growing movement across the country, following in the footsteps of states like Oregon and Colorado, which have already established legal frameworks for psychedelic-assisted treatment.
A second measure, House Bill 628, introduced by Assemblymember Linda Rosenthal (D) with eight co-sponsors, takes a broader approach. If passed, the legislation would legalize the adult possession and use of several plant- and fungus-based hallucinogens, including psilocybin, mescaline, DMT, ibogaine, and psilocin. The bill is currently under review by the state’s public health committee and, if advanced, would require approval from Governor Kathy Hochul (D) to become law.
Momentum for these reforms received a boost with the recent filing of Senate Bill S5303 by State Senator Julia Salazar (D). The measure serves as a companion bill to A2142, signaling increased legislative interest in the possibility of a hearing on psychedelic policy in Albany later this year. According to NYMHA leaders, this marks a critical step in New York’s efforts to bring psychedelic-assisted therapy into the mainstream.
Jonah Martindale, Rick Doblin, Gina Giorgio
“We are seeing that in the last few years, there has been a shift in the popularity of alternative treatments for the worsening mental health crisis, such as psychedelics,” said Jonah Martindale, a New York City resident, NYMHA coalition member, and advocate with Students for Sensible Drug Policy (SSDP). “The openness of various politicians across the political spectrum for these bills seems to reflect that. Now is the time to keep building momentum.”
Supporters of the bills argue that psychedelic-assisted therapy has the potential to revolutionize mental health care, offering new hope for individuals suffering from treatment-resistant conditions such as PTSD, depression, and substance use disorders. Medical research and clinical trials have shown promising results in recent years, prompting lawmakers in various states to reconsider their stance on these substances.
However, despite the growing enthusiasm, challenges remain. Critics have raised concerns about public safety, regulatory oversight, and the potential for misuse. Law enforcement officials and some health professionals caution that broader legalization could lead to unintended consequences, particularly if access to psychedelics is not accompanied by rigorous safety protocols.
Linked In Post – Jon Dennis, Psychedelic Lawyer: Washington SB 5201, the regulated psilocybin access bill, was considered today by the Senate Committee on Labor & Commerce ( 18 Feb 2025)
Washington SB 5201, the regulated psilocybin access bill, was considered today by the Senate Committee on Labor & Commerce. The bill would require low-income and other taxpayers to subsidize regulated access that is cost-prohibitive for many, while continuing to criminalize the same activities outside of the regulated marketplace.
For context, Oregon’s regulated system was promised to be self-funded by licensing fees and sales taxes, but the program needed a $3.1MM bailout in 2023, and the program is now seeking an additional $3.5MM bailout from the legislature. This is despite already-exorbitant licensing fees, including a $2,000 annual fee for facilitators. (By contrast, the annual fee for an Oregon law license is $683; the annual fee for medical doctors is $702.)
Taxing residents for the administration of a costly access program, while criminalizing affordable access outside the program, is problematic–particularly in Washington where local governments representing 14% of the entire population have already called on state lawmakers to decriminalize psilocybin and other plant-based psychedelic substances. Washington lawmakers must do better and not ignore the socio-economic and criminal justice impacts of a regulated-only access program.